xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

126

KUANetal.

TABLE XIV.3 Evidence surrounding neutron therapy in treatment of sinonasal tumors.

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Aljabab et al. 461

1. LC90% 2. PFS79% 3. OS93% 4. Late grade 3/4 events included trismus ( n = 1), hearing loss ( n = 2), visual loss ( n = 6), and bone necrosis ( n = 1) 1. DFS68% 2. OS62% 3. Complications of the treatment were registered in 39.4% of patients

1. LC 2. PFS 3. OS

2021

4

Retrospective case series

Combined proton

neutron for salivary tumors (SNM n = 12)

Novikov et al. 541 2015 4

Retrospective case series

SNM at single institute treated with NRT

1. 5-year DFS 2. 5-year OS

(postop n = 46, gamma + NRT n = 45) carcinoma at a single institute (SNM n = 43)

Douglas et al. 463 2003 4

1. LRC59% 2. CCS67% 3. G3 + tox 10%

1. 6-year LRC 2. 6-year CCS 3. 6-year G3 + tox 1. 5-year LC neu

Retrospective case series

Salivary gland

Huber et al. 542

2001 4

Retrospective case series

ACC at a single

1. 75/32 2. Severe late grade 3 and 4 toxicity tended to be more prevalent ( p > 0.1) with neutrons (19%) than with mixed beam (10%) and photons (4%)

institute (SNM n = 12 with NRT or mixed with photons)

trons/mixed

2. Toxicity

Douglas et al. 543

1. LRC57% 2. CCS77% 3. OS72%

1. 5-year LRC 2. 5-year CCS 3. 5-year OS 1. 5-year LRC 2. 5-year CCS 3. 5-year OS

2000 4

Retrospective case series

ACC at a single

institute (SNM n = 32)

Douglas et al. 544 1996 4

Retrospective case series

ACC at a single

1. LRC47% 2. CCS64% 3. OS59% 4. Patients without involvement of the cavernous sinus, base of skull, or nasopharynx (51 patients) had a 5-year actuarial LRC rate of 59%, whereas LRC was significantly lower (15%) for patients with tumors involving these sites

institute (SNM n = 27)

Buchholz et al. 545

1. LRC63% 2. DFS93% 3. OS65%

1. 5-year LRC 2. 5-year DFS 3. 5-year OS

1993 4

Retrospective case series

ACC at a single

institute (SNM n = 7)

Saroja et al. 546

1987 4

Retrospective case series

Salivary gland

1. LC 2. Toxicity

1. LC27% 2. 23% had major morbidity directed related to the total dose delivered

carcinoma at a single institute (SNM n = 19)

Errington 547

1. LC50% 2. OS30% 3. Complication 30%

1986 4

Retrospective case series

SNM at single institute ( n = 43)

1. 5-year LC 2. 5-year OS 3. 2-year

Complication

(Continues)